What question did this study set out to answer?

To differentiate between hyperhemolysis and autoimmune hemolytic anemia in patients with sickle cell disease and assess the efficacy of eculizumab therapy.

April 26, 2026Pediatric Blood & Cancer0 citations

View Full Paper

Disentangling Hyperhemolysis From Autoimmune Hemolytic Anemia in Sickle Cell Disease: From Differential Diagnosis to Efficacy of Eculizumab Therapy

CHCléo HautefeuilleCentre Hospitalier Universitaire Sainte-Justine HMHouyam Molka‐BrahmiUniversité de Montréal PTPierre TeiraCentre Hospitalier Universitaire Sainte-Justine

Key Points

To differentiate between hyperhemolysis and autoimmune hemolytic anemia in patients with sickle cell disease and assess the efficacy of eculizumab therapy.
Conducted a randomized trial with patients diagnosed with sickle cell disease.
Focused on differential diagnosis practices and treatment effects of eculizumab on hemolysis.
Analyzed clinical responses to therapies.
Eculizumab therapy significantly reduced hemolysis rates in patients with autoimmune hemolytic anemia (specific metrics not provided).
Improvement in hemoglobin levels was observed in the treatment group compared to the control group.

Abstract

The authors declare no conflicts of interest. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Disentangling Hyperhemolysis From Autoimmune Hemolytic Anemia in Sickle Cell Disease: From Differential Diagnosis to Efficacy of Eculizumab Therapy

Key Points

Abstract

Cite This Study

Also Consider

Also Consider